Is there a role for surgery for patients with a complete clinical response after chemoradiation for esophageal cancer? An intention-to-treat case-control study

Annals of Surgery

Volumn 258, Issue 5, 2013, Pages 793-800

  Piessen, Guillaume ^a,b,c   Messager, Mathieu ^a,b,c   Mirabel, Xavier ^d,e   Briez, Nicolas ^a,b   Robb, William B ^a,b   Adenis, Antoine ^e   Mariette, Christophe ^a,b,c  

^a LILLE UNIVERSITY HOSPITAL   (France)

^b UNIV LILLE   (France)

^c JEAN PIERRE AUBERT RESEARCH CENTER   (France)

^d Academic Radiotherapy Department   (France)

^e CENTRE RENÉ GAUDUCHEAU   (France)

Author keywords

Chemoradiation; Complete responders; Esophageal cancer; Locoregional control; Surgery; Survival

Indexed keywords

CISPLATIN; FLUOROURACIL;

ADULT; AGED; ANASTOMOSIS LEAKAGE; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SPECIFIC SURVIVAL; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CHEMORADIOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DISEASE FREE SURVIVAL; ENDOSCOPY; ESOPHAGUS BIOPSY; ESOPHAGUS CANCER; ESOPHAGUS RESECTION; FEMALE; FOLLOW UP; HUMAN; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MALE; MALNUTRITION; MORBIDITY; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NUTRITIONAL STATUS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SQUAMOUS CELL CARCINOMA; SURGICAL MORTALITY; SURGICAL RISK; SURVIVAL RATE; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AGED; BIOPSY; CASE-CONTROL STUDIES; CHEMORADIOTHERAPY; COMBINED MODALITY THERAPY; ESOPHAGEAL NEOPLASMS; ESOPHAGECTOMY; ESOPHAGOSCOPY; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; SURVIVAL RATE; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 84886094608     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0000000000000228     Document Type: Article

References (36)

1. Mariette C, Piessen G, Triboulet JP. Therapeutic strategies in oesophageal carcinoma: role of surgery and other modalities. Lancet Oncol. 2007;8: 545-553. (Pubitemid 46813024)
2. Tepper J, Krasna MJ, Niedzwiecki D, et al. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol. 2008;26:1086-1092.
3. vanHagen P, Hulshof MC, van Lanschot JJ, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012;366:2074-2084.
4. Sjoquist KM, Burmeister BH, Smithers BM, et al. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol. 2011;12:681-692.
5. Mariette C, Piessen G, Briez N, et al. Oesophagogastric junction adenocarcinoma: which therapeutic approach? Lancet Oncol. 2011;12:296-305.
6. Stahl M, Stuschke M, Lehmann N, et al. Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol. 2005;23:2310-2317. (Pubitemid 46218723)
7. Bedenne L, Michel P, Bouché O, et al. Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. J Clin Oncol. 2007;25:1160-1168. (Pubitemid 46640561)
8. Swisher SG, Winter KA, Komaki RU, et al. A phase II study of a paclitaxelbased chemoradiation regimen with selective surgical salvage for resectable locoregionally advanced esophageal cancer: initial reporting of RTOG 0246. Int J Radiat Oncol Biol Phys. 2012;82:1967-1972.
9. Swisher SG, Maish M, Erasmus JJ, et al. Utility of PET, CT, and EUS to identify pathologic responders in esophageal cancer. Ann Thorac Surg. 2004;78:1152-1160. (Pubitemid 39303827)
10. Jones DR, Parker LA, Jr, Detterbeck FC, et al. Inadequacy of computed tomography in assessing patients with esophageal carcinoma after induction chemoradiotherapy. Cancer. 1999;85:1026-1032. (Pubitemid 29115579)
11. Laterza E, de Manzoni G, Guglielmi A, et al. Endoscopic ultrasonography in the staging of esophageal carcinoma after preoperative radiotherapy and chemotherapy. Ann Thorac Surg. 1999;67:1466-1469. (Pubitemid 29320258)
12. Piessen G, Petyt G, Duhamel A, et al. Ineffectiveness of 18Ffluorodeoxyglucose positron emission tomography in the evaluation of tumor response after completion of neoadjuvant chemoradiation in esophageal cancer. Ann Surg. 2013;258:66-76.
13. Lim JT, Truong PT, Berthelet E, et al. Endoscopic response predicts for survival and organ preservation after primary chemoradiotherapy for esophageal cancer. Int J Radiat Oncol Biol Phys. 2003;57:1328-1335. (Pubitemid 37443973)
14. Crehange G, Maingon P, Peignaux K, et al. Phase III trial of protracted compared with split-course chemoradiation for esophageal carcinoma: Federation Francophone de Cancerologie Digestive 9102. J Clin Oncol. 2007;25:4895-48901.
15. Di Fiore F, Lecleire S, Rigal O, et al. Predictive factors of survival in patients treated with definitive chemoradiotherapy for squamous cell esophageal carcinoma. World J Gastroenterol. 2006;12:4185-4190. (Pubitemid 44376899)
16. 18F]fluorodeoxyglucose positron emission tomography (FDG-PET): can postchemoradiotherapy FDG-PET predict the utility of resection? J Clin Oncol. 2010;28:4714-4721.
17. Thésaurus National de Cancérologie Digestive. http://www.snfge.org/data/ModuleDocument/publication/5/pdf/TNCD-chapitre-1.pdf. Accessed January 2, 2013.
18. Adenis A, Mariette C, Mirabel X, et al. Acute respiratory disease syndrome with preoperative chronomodulated chemoradiotherapy in patients with esophageal cancer. Early termination of a phase I trial. Eur J Surg Oncol. 2008;34:30-35. (Pubitemid 350296771)
19. Mariette C, Seitz JF, Maillard E, et al. Surgery alone versus chemoradiotherapy followed by surgery for localized esophageal cancer: analysis of a randomized controlled phase III trial FFCD 9901. Proc Am Soc Clin Oncol. 2010;28:4005(abstr).
20. Westerterp M, van Westreenen HL, Reitsma JB, et al. Esophageal cancer: CT, endoscopic US, and FDG PET for assessment of response to neoadjuvant therapy-systematic review. Radiology. 2005;236:841-851. (Pubitemid 41170846)
21. Suzuki A, Xiao L, Hayashi Y, et al. Prognostic significance of baseline positron emission tomography and importance of clinical complete response in patients with esophageal or gastroesophageal junction cancer treated with definitive chemoradiotherapy. Cancer. 2011;117:4823-4833.
22. Mariette C, Piessen G, Briez N, et al. The number of metastatic lymph nodes and the ratio between metastatic and examined lymph nodes are independent prognostic factors in esophageal cancer regardless of neoadjuvant chemoradiation or lymphadenectomy extent. Ann Surg. 2008;247:365-371. (Pubitemid 351156783)
23. Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240:205-213. (Pubitemid 38963009)
24. Sobon LH, Gospodarowicz MK, Wittekind C, eds. UICC TNM Classification of Malignant Tumors. 7th ed. New York, NY: Wiley-Blackwell; 2009.
25. Mandard AM, Dalibard F, Mandard JC, et al. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations. Cancer. 1994;73:2680-2686. (Pubitemid 24166250)
26. Conroy T, Yatagh̀ene Y, Etienne PL, et al. Phase II randomised trial of chemoradiotherapy with FOLFOX4 or cisplatin plus fluorouracil in oesophageal cancer. Br J Cancer. 2010;103:1349-1355.
27. Brown WA, Thomas J, Gotley D, et al. Use of oesophagogastroscopy to assess the response of oesophageal carcinoma to neoadjuvant therapy. Br J Surg. 2004;91:199-204. (Pubitemid 38233965)
28. Lightdale CJ, Kulkarni KG. Role of endoscopic ultrasonography in the staging and follow-up of esophageal cancer. J Clin Oncol. 2005;23:4483-4489. (Pubitemid 46196577)
29. Vallböhmer D, Hölscher AH, Dietlein M, et al. [18F]-Fluorodeoxyglucosepositron emission tomography for the assessment of histopathologic response and prognosis after completion of neoadjuvant chemoradiation in esophageal cancer. Ann Surg. 2009;250:888-894.
30. vanHeijl M, Omloo JM, van Berge Henegouwen MI, et al. Fluorodeoxyglucose positron emission tomography for evaluating early response during neoadjuvant chemoradiotherapy in patients with potentially curable esophageal cancer. Ann Surg. 2011;253:56-63.
31. Taketa T, Correa AM, Suzuki A, et al. Outcome of trimodality-eligible esophagogastric cancer patients who declined surgery after preoperative chemoradiation. Oncology. 2012;83:300-304.
32. Gardner-Thorpe J, Hardwick RH, Dwerryhouse SJ. Salvage oesophagectomy after local failure of definitive chemoradiotherapy. Br J Surg. 2007;94:1059-1066. (Pubitemid 350082848)
33. Wouters MW, Gooiker GA, van Sandick JW, et al. The volume-outcome relation in the surgical treatment of esophageal cancer: a systematic review and meta-analysis. Cancer. 2012;118:1754-1763.
34. van Hagen P, Wijnhoven BP, Nafteux P, et al. Recurrence pattern in patients with a pathologically complete response after neoadjuvant chemoradiotherapy and surgery for oesophageal cancer. Br J Surg. 2013;100:267-273.
35. Bouvier AM, Binquet C, Gagnaire A, et al. Management and prognosis of esophageal cancers: has progress been made? Eur J Cancer. 2006;42:228-233. (Pubitemid 43083494)
36. Bonnetain F, Bouché O, Michel P, et al. A comparative longitudinal quality of life study using the Spitzer quality of life index in a randomized multicenter phase III trial (FFCD 9102): chemoradiation followed by surgery compared with chemoradiation alone in locally advanced squamous resectable thoracic esophageal cancer. Ann Oncol. 2006;17:827-834.